 SEATTLE, May 02, 2022 GLOBE NEWSWIRE -- Sana Biotechnology, Inc. NASDAQ: SANA, a company focused on creating and delivering engineered cells as medicines, today announced that five abstracts covering preclinical data from its hypoimmune and fusogen platforms were accepted for either oral or poster presentation at the American Society of Gene and Cell Therapy ASGCT 25th Annual Meeting taking place May 16-19, 2022 in Washington, D.C. 